Business
HCi Viocare Announces Corporate Mandate to Raise up to 30 Million Euro
HCi Viocare Announces Corporate Mandate to Raise up to 30 Million Euro.
About this update from Rafina Innovations Inc.
[{"type":"text","content":"\n \n \n HCi Viocare Announces Corporate Mandate to Raise up to 30 Million Euro\n \n \nHCi Viocare Announces Corporate Mandate to Raise up to 30 Million Euro\n \n GLASGOW, SCOTLAND--(Marketwired - Apr 4, 2016) - HCi Viocare (OTCQB: VICA) (\"HCi Viocare\", the \"Company\") today announced its board of directors has agreed to source up to EUR 30 million in funding. Proceeds from the financing will be used for marketing its patent pending 'smart insole', the development of its other Smart Medical solutions, for general operating capital, as well as the expansion of its proposed chain of independent prosthetics and orthotics (P&O) and diabetic foot clinics.\n \"The financing will be instrumental in moving the Company forward in the Smart Medical field as well as expanding our base of prosthetic, orthotic and diabetic foot clinics,\" stated Sotiris Leontaritis, CEO and President of HCi Viocare.\n The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration, under the Act.\n Company website: www.hciviocare.com \n Glasgow clinic website: www.hci-viocare.co.uk \n Twitter: @HCiViocare\n Glasgow location:\n HCi Viocare, Kintyre House, 209 Govan Road, Glasgow G51 1HJ\n Forward Looking Statements\n This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as \"expects': \"intends\", \"estimates': \"projects\", \"anticipates': \"believes': \"could': and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the \"SEC'). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance ...